# reload+after+2024-01-23 16:43:37.628832
address1§One Main Street
address2§14th Floor
city§Cambridge
state§MA
zip§02142
country§United States
phone§617 252 0848
website§https://www.blackdiamondtherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§65
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mark A. Velleca M.D., Ph.D.', 'age': 59, 'title': 'CEO, President & Chairman', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 43886, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David M.  Epstein Ph.D.', 'age': 64, 'title': 'Co-Founder & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 885082, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fang  Ni Pharm.D.', 'age': 36, 'title': 'CFO, Principal Financial Officer and Chief Business Officer', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 656333, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brent  Hatzis-Schoch Esq., J.D.', 'age': 58, 'title': 'COO & General Counsel', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 683295, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Elizabeth  Buck Ph.D.', 'age': 48, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 340473, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erika  Jones', 'age': 38, 'title': 'VP of Finance, Corporate Controller & Principal Accounting Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth L. Montgomery', 'age': 51, 'title': 'Chief People Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sergey  Yurasov M.D., Ph.D.', 'age': 54, 'title': 'Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melanie  Morrison', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§10
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.579
currency§USD
dateShortInterest§1702598400
forwardEps§-2.09
exchange§NMS
quoteType§EQUITY
shortName§Black Diamond Therapeutics, Inc
longName§Black Diamond Therapeutics, Inc.
firstTradeDateEpochUtc§1580481000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§822eae7d-25a2-3ffc-8b26-04730bb0212d
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§10.0
targetMeanPrice§10.4
targetMedianPrice§10.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§5
quickRatio§9.575
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
